Mimedx (MDXG) Revenue (2011 - 2026)

Mimedx (MDXG) has 16 years of Revenue data on file, last reported at $59.0 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 33.12% year-over-year to $59.0 million; the trailing twelve-month figure through Mar 2026 stood at $389.4 million (up 10.51% YoY), and the FY2025 full-year result was $418.6 million, up 19.99% from the prior year.
• Revenue eased to $59.0 million in Q1 2026, from $118.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $118.1 million in Q4 2025 to a low of $58.9 million in Q1 2022.
• A 5-year average of $83.3 million and a median of $84.1 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 46.37% in 2022 and tumbled 33.12% in 2026, its largest moves.
• Tracing MDXG's Revenue over 5 years: stood at $74.4 million in 2022, then increased by 16.75% to $86.8 million in 2023, then rose by 7.0% to $92.9 million in 2024, then gained by 27.11% to $118.1 million in 2025, then sank by 50.05% to $59.0 million in 2026.
• Business Quant data shows MDXG's Revenue at $59.0 million in Q1 2026, $118.1 million in Q4 2025, and $113.7 million in Q3 2025.